Effects of necroptosis induced by receptor interacting-protein 3 in traumatic brain injury model of C57/BL mice

doi:10.3877/cma.j.issn.2095-9141.2017.05.006

Abstract

Abstract:

Objective

To investigate the effects of necroptosis induced by receptor interacting-protein 3 (RIP3) on traumatic brain injury (TBI) model of C57BL/6 mice and its mechanisms.

Methods

C57BL/6 mice were positioned beneath the controlled cortical impactor device (CCI) and subjected to impact injury at 1 mm depth of penetration, for a sustained depression of 120 msec and a velocity of 5 m/s. Ctrl group was not treated. Sham group was received craniotomy, without CCI injury. TBI group was received CCI injury and 4 μl DMSO injected. GSK’872 group was received CCI injury and 4 μl GSK’872 injected. Then, the degree of injury was detected by modified neurological severity scores (mNSS), the degree of brain edema was measured with drying wet method, the injure degree of cortex and hippocampus was assessed by HE staining, the recovery after CCI was measured by awakening time and the expressions of RIP3/RIP1/MLKL, Akt/p-Akt/mTOR/p-mTOR, Caspase-8/XIAP, Caspase-1/NLRP3 were detected by Western blot assay.

Results

Compared with TBI group, GSK’872 could significantly decrease the score of mNSS [1 d: (11.95±1.50) vs (13.05±1.82), t=2.084, P<0.05; 3 d: (8.95±1.39) vs (11.00±2.10), t=3.634, P<0.01: 5 d: (6.75±1.33) vs (8.90±1.52), t=4.759, P<0.01; 7 d: (4.00±1.08) vs (7.15±1.09), t=9.200, P<0.01], decrease the degree of brain edema [(77.91±0.84)% vs (80.34±0.94)%, t=8.692, P<0.01], reduce the degree of injury in cortex and hippocampus, and promote the awaking of mice after CCI[(4.08±0.63) h vs (5.11±0.74) h, t=4.717, P<0.01]. Furthermore, Western blotting assay reveled that GSK’872 could significantly decrease the levels of RIP3[(0.70±0.03) vs(1.04±0.04), t=13.051, P<0.01], RIP1[(0.93±0.02) vs (1.16±0.03), t=11.203, P<0.01], MLKL[(0.75±0.04) vs (1.03±0.03), t=9.873, P<0.01], Akt[(0.55±0.04) vs (0.77±0.05), t=6.278, P<0.01], p-Akt[(0.80±0.04) vs (0.99±0.04), t=6.217, P<0.01], mTOR[(0.48±0.05) vs (0.90±0.05), t=10.608, P<0.05], p-mTOR[(0.59±0.06) vs (1.00±0.05), t=9.144, P<0.01], Caspase-1[(0.80±0.04) vs (0.98±0.05), t=5.226, P<0.01], NLRP3[(0.51±0.03) vs (0.89±0.03), t=15.590, P<0.01], XIAP[(0.50±0.03) vs (0.83±0.03), t=13.340, P<0.01], but increase the level of Caspase-8 compared with TBI group [(0.83±0.03) vs (0.71±0.03), t=5.044, P<0.01].

Conclusion

Necroptosis induced by RIP3 may play an important role in TBI, however, GSK’872 could reduce the degree of injury after TBI, which reveals that RIP3 may be a new target for clinical treatment of TBI in the future.

Key words: Receptor-interacting protein3, Traumatic brain injury, Necroptosis

Zeqi Yu, Tailong Yi, Yue Tu, Xiaosa Yang, Jipeng Jiang, Xiaoyu Dong, Sai Zhang, Shixiang Cheng. Effects of necroptosis induced by receptor interacting-protein 3 in traumatic brain injury model of C57/BL mice[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2017, 03(05): 277-283.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2017.05.006

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2017/V03/I05/277

Figures/Tables 8

References 31

[1]	Mckee AC,Daneshvar DH. The neuropathology of traumatic brain injury[J]. Handb Clin Neurol, 2015, 127: 45-66.
[2]	Mazzeo AT,Filippini C,Rosato R, et al. Multivariate projection method to investigate inflammation associated with secondary insults and outcome after human traumatic brain injury: a pilot study[J]. J Neuroinflammation, 2016, 13(1): 157.
[3]	Bleriot C,Lecuit M. The interplay between regulated necrosis and bacterial infection[J]. Cell Mol Life Sci, 2016, 73(11-12): 2369-2378.
[4]	Takemoto K,Hatano E,Iwaisako K, et al. Necrostatin-1 protects against reactive oxygen species (ROS）-induced hepatotoxicity in acetaminophen-induced acute liver failure[J]. FEBS Open Bio, 2014, 4: 777-787.
[5]	Karunakaran D,Geoffrion M,Wei L, et al. Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis[J]. Sci Adv, 2016, 2(7): e1600224.
[6]	Xu Y,Wang J,Song X, et al. RIP3 induces ischemic neuronal DNA degradation and programmed necrosis in rat via AIF[J]. Sci Rep, 2016, 6: 29362.
[7]	Kitur K,Wachtel S,Brown A, et al. Necroptosis promotes staphylococcus aureus clearance by inhibiting excessive inflammatory signaling[J]. Cell Rep, 2016, 16(8): 2219-2230.
[8]	Bozec D,Iuga AC,Roda G, et al. Critical function of the necroptosis adaptor RIPK3 in protecting from intestinal tumorigenesis[J]. Oncotarget, 2016, 7(29): 46384-46400.
[9]	Zhang DW,Shao J,Lin J, et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis[J]. Science, 2009, 325(5938): 332-336.
[10]	Su Z,Yang Z,Xie L, et al. Cancer therapy in the necroptosis era[J]. Cell Death Differ, 2016, 23(5): 748-756.
[11]	Das A,McDonald DG,Dixon-Mah YN, et al. RIP1 and RIP3 complex regulates radiation-induced programmed necrosis in glioblastoma[J]. Tumour Biol, 2016, 37(6): 7525-7534.
[12]	Gerges S,Rohde K,Fulda S. Cotreatment with Smac mimetics and demethylating agents induces both apoptotic and necroptotic cell death pathways in acute lymphoblastic leukemia cells[J]. Cancer Lett, 2016, 375(1): 127-132.
[13]	Zaidi HA,Zabramski JM,Safavi-Abbasi S, et al. Spontaneous intracerebral hemorrhage[J]. World Neurosurg, 2015, 84(5): 1191-1192.
[14]	Liu T,Bao YH,Wang Y, et al. The role of necroptosis in neurosurgical diseases[J]. Braz J Med Biol Res, 2015, 48(4): 292-298.
[15]	Degterev A,Hitomi J,Germscheid M, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins[J]. Nat Chem Biol, 2008, 4(5): 313-321.
[16]	Sun L,Wang H,Wang Z, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase[J]. Cell, 2012, 148(1-2): 213-227.
[17]	Galluzzi L,Kepp O,Kroemer G. MLKL regulates necrotic plasma membrane permeabilization[J]. Cell Res, 2014, 24(2): 139-140.
[18]	He S,Wang L,Miao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha[J]. Cell, 2009, 137(6): 1100-1111.
[19]	Liu T,Zhao DX,Cui H, et al. Therapeutic hypothermia attenuates tissue damage and cytokine expression after traumatic brain injury by inhibiting necroptosis in the rat[J]. Sci Rep, 2016, 6: 24547.
[20]	Noshita N,Lewén A,Sugawara T, et al. Akt phosphorylation and neuronal survival after traumatic brain injury in mice[J]. Neurobiol Dis, 2002, 9(3): 294-304.
[21]	Crino PB. The mTOR signalling cascade: paving new roads to cure neurological disease[J]. Nat Rev Neurol, 2016, 12(7): 379-392.
[22]	Park J,Zhang J,Qiu J, et al. Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice[J]. J Cereb Blood Flow Metab, 2012, 32(2): 330-340.
[23]	Liu Q,Qiu J,Liang M, et al. Akt and mTOR mediate programmed necrosis in neurons[J]. Cell Death Dis, 2014, 5: e1084.
[24]	Günther C,Martini E,Wittkopf N, et al. Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis[J]. Nature, 2011, 477(7364): 335-339.
[25]	Kim JW,Choi EJ,Joe CO. Activation of death-inducing signaling complex (DISC) by pro-apoptotic C-terminal fragment of RIP[J]. Oncogene, 2000, 19(39): 4491-4499.
[26]	Challa S,Chan FK. Going up in flames: necrotic cell injury and inflammatory diseases[J]. Cell Mol Life Sci, 2010, 67(19): 3241-3253.
[27]	Kaiser WJ,Sridharan H,Huang C, et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL[J]. J Biol Chem, 2013, 288(43): 31268-31279.
[28]	Wallach D,Kang TB,Dillon CP, et al. Programmed necrosis in inflammation: Toward identification of the effector molecules[J]. Science, 2016, 352(6281): aaf2154.
[29]	Newton K,Manning G. Necroptosis and inflammation[J]. Annu Rev Biochem, 2016, 85: 743-763.
[30]	Pasparakis M,Vandenabeele P. Necroptosis and its role in inflammation[J]. Nature, 2015, 517(7534): 311-320.
[31]	Menu P,Vince JE. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly[J]. Clin Exp Immunol, 2011, 166(1): 1-15.

Please choose a citation manager

Content to export